Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 4, 2010, Pages 494-499

  Verhelst, Xavier ^a   Orlent, Hans ^b   Colle, Isabelle ^a   Geerts, Anja ^a   De Vos, Martine ^a   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b AZ Sint Jan ^*  (Belgium)

Author keywords

Anti TNF therapy; Hepatitis B virus infection; Immunosuppression; Liver failure; Reactivation; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; HEPATITIS B SURFACE ANTIGEN; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS B; DISEASE ASSOCIATION; DISEASE EXACERBATION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER FAILURE; MALE; MEDICAL RECORD REVIEW; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCREENING; SUBFULMINANT HEPATITIS B; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 77949446497     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283329d13     Document Type: Article

References (32)

1. Present DH, Rutgeers P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
2. Lipsky PE, Van-der-Heijde DM, St-Clair EW, Furst DE, Breedveld FC, Kalde JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumour necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343:1594-1602.
3. Van den Bosch F, Baeten D, Kruithof E, De Keyser F, Mielants H, Veys EM. Effects of loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in spondylarthropathy: an open pilot study. Ann Rheum Dis 2000; 59:428-433.
4. Olsen NJ, Stein CM. New Drugs for rheumatoid arthritis. N Engl J Med 2004; 350:2167-2179.
5. Ellerin T, Rubin RH,Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48:3013-3022.
6. Robinson H, Walker-Bone K. Anti-TNF-a therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology 2009; 48:450-451.
7. WHO Hepatitis B fact sheet, http://www.who.int/mediacentre/factsheets/ fs204/en/
8. O'Grady JG, Graeme JM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439-445.
9. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65:983-989.
10. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003; 30:1624-1625.
11. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62:686-687.
12. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, Claudepierre P. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31:107-109.
13. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63 (Suppl 2): ii18-ii24.
14. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53:1363-1365.
15. Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50:163-166.
16. Anelli MG, Torres DD, Manno C, Scioscia C, Iannone F, Covelli M, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005; 52:2519-2520.
17. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006; 45:1294-1297.
18. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008; 35:421-424.
19. Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64:788-789.
20. Kaur P, Chan V, Berney S. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 2008; 27:1069-1071.
21. Kaiser T, Moessner J, Patel K, McHutchinson J, Tillman H. Life threatening liver disease during treatment with monoclonal antibodies. BMJ 2009; 338:b508.
22. Perillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:1009-1022.
23. Saag KG, Teng GG, Oatjar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762-784.
24. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
25. Colle I, Adler M, Brenard R, Henrion J, Langlet P, Michielsen P, et al. Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines. Acta Gastroentero Belg 2007; 70:389-420.
26. Lok A, McMahon B. AASLD practice guidelines. Chronic hepatitis B. Hepatology 2007; 45:507-539.
27. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-a therapy: guidelines for clinical approach. J Gastroenterol and Hepatol 2006; 21:1366-1371.
28. ECCO statements on management of opportunistic infections in IBD patients. (unpublished report).
29. Saab S, Dong M, Joseph T, Tong M. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision model analysis. Hepatology 2007; 46:1049-1056.
30. Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007;13:125-140.
31. Beckebaum S, Sotiropoulos G, Gerken G, Cincinnati V. Hepatitis B and liver transplantation: 2008 update. Rev Med Virol 2009; 19:7-29.
32. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for chronic hepatits B. N Engl J Med 2008; 23:2442-2455.